The impact of HMGB2 knockdown on the invasive abilities of eight cancer cell lines representing breast cancer, cervical cancer, ovarian cancer, and endometrial cancer was analyzed using the Transwell invasion assay. Here, HMGB2 is linked to ovarian carcinoma.